IL22抗体;IL22 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using IL22 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using IL22 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of MOLT4 cells using IL22 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using IL22 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using IL22 mouse mAb with DAB staining.    

  
  

Interleukin-22 (IL-22) is a cytokine belonging to the IL-10 family, primarily produced by immune cells such as Th17 cells, γδ T cells, and innate lymphoid cells. It plays a dual role in modulating inflammatory responses and promoting tissue repair by targeting epithelial and stromal cells. IL-22 binds to a heterodimeric receptor complex (IL-22R1 and IL-10R2), activating downstream signaling pathways like JAK/STAT, which regulate cell survival, antimicrobial peptide production, and barrier integrity. Dysregulated IL-22 signaling is implicated in autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) and chronic inflammatory conditions, but it also exhibits protective effects in mucosal infections and tissue injury.

IL-22-neutralizing antibodies have emerged as therapeutic candidates to block pathogenic IL-22 activity in autoimmune disorders. These monoclonal antibodies bind IL-22 or its receptor, inhibiting pro-inflammatory signaling. Conversely, agonist antibodies or IL-22 fusion proteins are being explored to enhance tissue repair in conditions like ulcerative colitis or liver fibrosis. Current research focuses on optimizing antibody specificity, pharmacokinetics, and safety profiles. Challenges include balancing IL-22's context-dependent roles and minimizing off-target effects. Several IL-22-targeting biologics are in preclinical or early clinical trials, highlighting their potential in precision immunotherapy.